{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:57:29Z","timestamp":1793969849385,"version":"4.8.0"},"reference-count":34,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DHPS"],"DOI":"10.2147\/dhps.s257009","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T19:52:55Z","timestamp":1604951575000},"page":"207-215","source":"Crossref","is-referenced-by-count":27,"title":["<p>Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database<\/p>"],"prefix":"10.2147","volume":"Volume 12","author":[{"given":"Yumi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4161\/viru.26515","volume":"5","author":"Lewis","year":"2014","journal-title":"Virulence"},{"key":"ref2","unstructured":"Soliris Review Report (October 16, 2019). Available from http:\/\/www.pmda.go.jp\/drugs\/2019\/P20191205001\/870056000_22200AMX00316_A100_1.pdf. Accessed January 17, 2020."},{"key":"ref3","unstructured":"Soliris Review Report (November 24, 2017). Available from http:\/\/www.pmda.go.jp\/drugs\/2018\/P20180110001\/870056000_22200AMX00316_A100_2.pdf. Accessed January 17, 2020."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","volume":"367","author":"Thompson","year":"2006","journal-title":"Lancet"},{"key":"ref5","unstructured":"European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. Available from https:\/\/www.ecdc.europa.eu\/en\/meningococcal-disease\/factsheet. Accessed January 3, 2020."},{"key":"ref6","unstructured":"The Department of Health. Meningococcal Disease (Invasive). Available from https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/ohp-meningococcal-W.htm. Accessed January 12, 2020."},{"key":"ref7","unstructured":"Public health surveillance. Information for New Zealand Public Health Action. Invasive meningococcal disease report. Available from https:\/\/surv.esr.cri.nz\/PDF_surveillance\/MeningococcalDisease\/2019\/MeningococcalDisease_wk2-32019.pdf"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3201\/eid2307.160129","volume":"23","author":"Olea","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/INF.0000000000001429","volume":"36","author":"Gentile","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.14745\/ccdr.v40i09a01","volume":"40","author":"Li","year":"2014","journal-title":"Can Comm Dis Rep"},{"key":"ref11","unstructured":"Centers for Disease Control and Prevention. Meningococcal disease. Available from https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt08-mening.pdf. Accessed July 24, 2020."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/infdis\/jiz355","volume":"220","author":"Fernandez","year":"2019","journal-title":"J Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1016\/j.vaccine.2016.06.018","volume":"34","author":"Fukusumi","year":"2016","journal-title":"Vaccine"},{"key":"ref14","unstructured":"National Institute of Infectious Diseases. Invasive meningococcal infection April 2013-October 2017. IASR. 2018;39:1\u20132."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"B64","DOI":"10.1016\/j.vaccine.2009.04.061","volume":"27","author":"Caugant","year":"2009","journal-title":"Vaccine"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.11150\/kansenshogakuzasshi1970.79.527","volume":"79","author":"Tanaka","year":"2005","journal-title":"Kansenshogaku Zasshi"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3999\/jscpt.46.185","volume":"46","author":"Mori","year":"2015","journal-title":"Jpn J Clin Pharmacol Ther"},{"key":"ref18","unstructured":"The Portal Site of Official Statistics of Japan, e-Stat. Population Estimates. Available from https:\/\/www.e-stat.go.jp\/stat-search?page=1&layout=normal&toukei=00200524&survey=%E4%BA%BA%E5%8F%A3. Accessed January 21, 2020."},{"key":"ref19","unstructured":"Pharmaceuticals and Medical Devices Agency. ADR information for eculizumab from the first quarter of 2010 to the second quarter of 2019. Available from: https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0003.html. Accessed January 3, 2020"},{"key":"ref20","unstructured":"Alexion Pharma Co., Ltd. Safety information for Soliris\u00ae Intravenous Infusion 300 mg (Created in October 2016). Available from http:\/\/www.soliris.jp\/common\/pdf\/SOL_safty.pdf. Accessed January 18, 2020."},{"key":"ref21","unstructured":"Alexion Pharma Co., Ltd. SOLIRIS\u00ae Intravenous Infusion 300 Mg [Package Insert]. 8th edition. Japanese; 2017."},{"key":"ref22","unstructured":"Alexion Pharma Co., Ltd. Soliris\u00ae Patient Safety Card SOL-Card-1709 Japanese; 2015."},{"key":"ref23","unstructured":"Alexion Pharma Co., Ltd. Safety information for Soliris\u00ae Intravenous Infusion 300 mg 2nd report (published in Mar 2018) Available from http:\/\/www.soliris.jp\/common\/pdf\/sol_safty2.pdf. Accessed February 2, 2020."},{"key":"ref24","unstructured":"Japanese Society of Hematology. Notes and countermeasures when using Soliris. Available from http:\/\/www.jshem.or.jp\/uploads\/files\/medical\/ 20180424%20Soliris.pdf. Accessed February 2, 2020."},{"key":"ref25","unstructured":"Japanese Society of Nephrology. Notes and countermeasures when using Soliris. Available from https:\/\/www.jsn.or.jp\/topics\/notice\/_3430.php. Accessed February 2, 2020."},{"key":"ref26","unstructured":"Japanese Society of Neurology. Notes on using Soliris\u00ae approved for systemic myasthenia gravis. Available from https:\/\/www.neurology-jp.org\/news\/news_ 20180109_01.html. Accessed February 2, 2020."},{"key":"ref27","unstructured":"Japanese Society of Pediatrics. Attention about meningococcal disease caused by administration of Soliris (eculizumab) IV 300 mg. Available from https:\/\/www.jpeds.or.jp\/uploads\/files\/201805Soliris.pdf. Accessed February 2, 2020."},{"key":"ref28","volume-title":"Regulatory Aspects of Pharmacovigilance. In: An Introduction to Pharmacovigilance. Second Edition","year":"2018"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12185-016-2065-4","volume":"104","author":"Ninomiya","year":"2016","journal-title":"Int J Hematol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"Soci\u00e9","year":"2019","journal-title":"Br J Haematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3201\/eid2408.180228","volume":"24","author":"Nolfi-Donegan","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"ref32","first-page":"2802","volume":"14","author":"Polat","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1080\/21645515.2018.1451810","volume":"14","author":"Dretler","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"McNamara","year":"2017","journal-title":"Morb Mortal Wkly Rep"}],"container-title":["Drug, Healthcare and Patient Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=63518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=63518","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T19:53:21Z","timestamp":1604951601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/risk-analysis-of-eculizumab-related-meningococcal-disease-in-japan-usi-peer-reviewed-article-DHPS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2147\/dhps.s257009","relation":{},"ISSN":["1179-1365"],"issn-type":[{"value":"1179-1365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}